Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06975605
Registration number
NCT06975605
Ethics application status
Date submitted
11/04/2025
Date registered
16/05/2025
Date last updated
5/06/2025
Titles & IDs
Public title
Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs.
Query!
Scientific title
Phase 1, Open-label, 3-period Study to Evaluate Drug-Drug Interaction Potential of Radiprodil With Cocktail Probes Representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP in Healthy Adult Subjects
Query!
Secondary ID [1]
0
0
RAD-GRIN-506
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Tuberous Sclerosis Complex (TSC)
0
0
Query!
Focal Cortical Dysplasia
0
0
Query!
Other Neurological Disorders
0
0
Query!
Condition category
Condition code
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Radiprodil + co-administered drugs
Experimental: Experimental Cohort - Study Drug - Radiprodil will be administred using a sequential cocktail approach consisting of substrates of multipleCYP enzymes or transporters.
Treatment: Drugs: Radiprodil + co-administered drugs
Study drug radiprodil will be administered asbelow in a sequential manner.
- Radiprodil 7.5 mg, 15 mg and 30 mg will be administered in a sequential manner.
Co-administered drugs include: - Warfarin - 10 mg tablets, midazolam 1 mg, digoxin 0.25 mg, rosuvastatin 10 mg, omeprazole 20 mg, Vitamin K - 10 mg.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
To assess the effect of oral radiprodil on the plasma PK parameter (AUC) of single oral dose of warfarin following repeated oral doses of radiprodil.
Query!
Assessment method [1]
0
0
Blood samples will be assessed.
Query!
Timepoint [1]
0
0
Day1 - Predose, 0.5 hour,1 hour, 1.5, 2, 3, 4, 8, 12 Day 15 - 24 hours post dose, 48 hour, 96, 120, 144 hours
Query!
Primary outcome [2]
0
0
To assess the effect of oral radiprodil on the plasma PK parameter (CMax) of single oral dosing of warfarin following repeated oral dosing of radiprodil.
Query!
Assessment method [2]
0
0
Blood plasma samples will be assessed
Query!
Timepoint [2]
0
0
Blood samples for plasma PK will be collected on the following days. - S-warfin - Day1 - Predose, 0.5 hour,1 hour, 1.5, 2, 3, 4, 8, 12 Day 15 - 24 hours post dose, 48 hour, 96, 120, 144 hours
Query!
Primary outcome [3]
0
0
To assess the effect of oral radiprodil on the plasma PK parameter (AUC) of single oral dose of midazolam following repeated oral doses of radiprodil.
Query!
Assessment method [3]
0
0
Blood plasma samples will be assessed
Query!
Timepoint [3]
0
0
Day 1 - Pre-dose, 0.5, 1, 1.5, 2, 3, 4 , 8, 12, 24 hour day 15- 24 hour post dose -
Query!
Primary outcome [4]
0
0
To assess the effect of oral radiprodil on the plasma PK parameter (CMax) of single oral dosing of midazolam following repeated oral dosing of radiprodil
Query!
Assessment method [4]
0
0
Blood plasma samples will be assessed
Query!
Timepoint [4]
0
0
Day 1 - Pre-dose, 0.5, 1, 1.5, 2, 3, 4 , 8, 12, 24 hour day 15- 24 hour post dose -Digoxin- Day 3- predose, 0.5 hour, 1 , 1.5, 2,3, 4, 8, 12, 24 hour Day 17 - 24 hour post dose.
Query!
Primary outcome [5]
0
0
To assess the effect of oral radiprodil on the plasma PK parameter (AUC) of single oral dose of digoxin following repeated oral doses of radiprodil.
Query!
Assessment method [5]
0
0
Blood plasma samples will be assessed
Query!
Timepoint [5]
0
0
Day 3- predose, 0.5 hour, 1 , 1.5, 2,3, 4, 8, 12, 24 hour Day 17 - 24 hour post dose
Query!
Primary outcome [6]
0
0
To assess the effect of oral radiprodil on the plasma PK parameter (CMax) of single oral dosing of digoxin following repeated oral dosing of radiprodil.
Query!
Assessment method [6]
0
0
Blood plasma samples will be assessed
Query!
Timepoint [6]
0
0
Day 3- predose, 0.5 hour, 1 , 1.5, 2,3, 4, 8, 12, 24 hour Day 17 - 24 hour post dose
Query!
Primary outcome [7]
0
0
To assess the effect of oral radiprodil on the plasma PK parameter (AUC) of single oral dose of rosuvastatin following repeated oral doses of radiprodil.
Query!
Assessment method [7]
0
0
Blood plasma samples will be assessed
Query!
Timepoint [7]
0
0
Day 3 - pre-dose, 0.5, 1,5, 2, 3, 4, 8, 12, 24 hour Day 17 - 24 hour post dose
Query!
Primary outcome [8]
0
0
To assess the effect of oral radiprodil on the plasma PK parameter (CMax) of single oral dosing of rosuvastatin following repeated oral dosing of radiprodil
Query!
Assessment method [8]
0
0
Blood plasma samples will be assessed
Query!
Timepoint [8]
0
0
Day 3 - pre-dose, 0.5, 1,5, 2, 3, 4, 8, 12, 24 hour Day 17 - 24 hour post dose
Query!
Primary outcome [9]
0
0
To assess the effect of oral radiprodil on the plasma PK parameter (AUC) of single oral dose of omeprazole following repeated oral doses of radiprodil.
Query!
Assessment method [9]
0
0
Blood plasma samples will be assessed
Query!
Timepoint [9]
0
0
Day 5 - pre-dose, 0.5, 1,5, 2, 3, 4, 8, 12, 24 hour Day 19 - 24 hourpost dose
Query!
Primary outcome [10]
0
0
To assess the effect of oral radiprodil on the plasma PK parameter (CMax) of single oral dosing of omeprazole following repeated oral dosing of radiprodil.
Query!
Assessment method [10]
0
0
Blood plasma samples will be assessed
Query!
Timepoint [10]
0
0
Day 5 - pre-dose, 0.5, 1,5, 2, 3, 4, 8, 12, 24 hour Day 19 - 24 hourpost dose
Query!
Secondary outcome [1]
0
0
To assess the safety of oral dosing of radiprodil co-administered with midazolam.
Query!
Assessment method [1]
0
0
Safety will be evaluated by: Incidence, severity and relationship of AEs, serious adverse events (SAEs), AESI, and withdrawals due to AEs
Query!
Timepoint [1]
0
0
Adverse events: will be assessed throughout the study period from Day -1 untill Day 24 (End of StudyVisit/Early Termination Visit) and Follow up (Telephone call) which is 30 days post last dose.
Query!
Secondary outcome [2]
0
0
To assess the safety of oral dosing of radiprodil co-administered with digoxin
Query!
Assessment method [2]
0
0
Safety will be evaluated by: • Incidence, severity and relationship of AEs, serious adverse events (SAEs), AESI, and withdrawals due to AEs
Query!
Timepoint [2]
0
0
Adverse events: will be assessed throughout the study period from Day -1 untill Day 24 (End of StudyVisit/Early Termination Visit) and Follow up (Telephone call) which is 30 days post last dose
Query!
Secondary outcome [3]
0
0
To assess the safety of oral dosing of radiprodil co-administered with rosuvastatin.
Query!
Assessment method [3]
0
0
Safety will be evaluated by Incidence, severity and relationship of AEs, serious adverse events (SAEs), AESI, and withdrawals due to AEs
Query!
Timepoint [3]
0
0
Adverse events: will be assessed throughout the study period from Day -1 untill Day 24 (End of StudyVisit/Early Termination Visit) and Follow up (Telephone call) which is 30 days post last dose
Query!
Secondary outcome [4]
0
0
To assess the safety of oral dosing of radiprodil co-administered with omeprazole
Query!
Assessment method [4]
0
0
Safety will be evaluated by Incidence, severity and relationship of AEs, serious adverse events (SAEs), AESI, and withdrawals due to AEs.
Query!
Timepoint [4]
0
0
Adverse events: will be assessed throughout the study period from Day -1 untill Day 24 (End of StudyVisit/Early Termination Visit) and Follow up (Telephone call) which is 30 days post last dose.
Query!
Secondary outcome [5]
0
0
To assess the safety of oral dosing of radiprodil co-administered with oral warfarin.
Query!
Assessment method [5]
0
0
Safety will be evaluated by Incidence, severity and relationship of AEs, serious adverse events (SAEs), AESI, and withdrawals due to AEs.
Query!
Timepoint [5]
0
0
Adverse events: will be assessed throughout the study period from Day -1 untill Day 24 (End of StudyVisit/Early Termination Visit) and Follow up (Telephone call) which is 30 days post last dose.
Query!
Secondary outcome [6]
0
0
12-lead ECG - Mean change in QT interval from baseline to end of treatment (oral dosing of radiprodil co-administered with midazolam)
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
12 lead ECG- Screening, Day -1, Day 1, Day 3, Day 5, Day 7-8, 9-10, 11-14, 15, 17, 19 and Day 24 (End of Study Visit/Early Termination Visit)
Query!
Secondary outcome [7]
0
0
12-lead ECG - Mean change in QT interval from baseline to end of treatment (oral radiprodil co-administered with digoxin)
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
12 lead ECG- Screening, Day -1, Day 1, Day 3, Day 5, Day 7-8, 9-10, 11-14, 15, 17, 19 and Day 24 (End of Study Visit/Early Termination Visit)
Query!
Secondary outcome [8]
0
0
12-lead ECG- Mean change from Baseline to End-of-Treatment in QT interval(oral dosing of radiprodil co-administered with rosuvastatin)
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
12 lead ECG- Screening, Day -1, Day 1, Day 3, Day 5, Day 7-8, 9-10, 11-14, 15, 17, 19 and Day 24 (End of Study Visit/Early Termination Visit)
Query!
Secondary outcome [9]
0
0
12-lead ECG- Mean change from Baseline to End-of-Treatment in QT interval (oral dosing of radiprodil co-administered with omeprazole)
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
12 lead ECG- Screening, Day -1, Day 1, Day 3, Day 5, Day 7-8, 9-10, 11-14, 15, 17, 19 and Day 24 (End of Study Visit/Early Termination Visit)
Query!
Secondary outcome [10]
0
0
To assess the safety of oral dosing of radiprodil co-administered with oral warfarin
Query!
Assessment method [10]
0
0
Change from baseline in clinical laboratory parameters(hematology, coagulation, clinical chemistry, and urinalysis). Clinical laboratory results assessed using blood and urine samples and will be classified as normal, abnormal not clinically significant (NCS), or abnormal CS.
Query!
Timepoint [10]
0
0
Clinical lab parameters- Screening, Day -1, Days 2-4, Days 6-14,Days 16-18, Days 20-21 and Day 24 (End of Study Visit/Early Termination Visit)
Query!
Secondary outcome [11]
0
0
To assess the safety of oral dosing of radiprodil co-administered with midazolam
Query!
Assessment method [11]
0
0
Change from baseline in clinical laboratory parameters(hematology, coagulation, clinical chemistry, and urinalysis). Clinical laboratory results assessed using blood and urine samples and will be classified as normal, abnormal not clinically significant (NCS), or abnormal CS.
Query!
Timepoint [11]
0
0
Clinical lab parameters- Screening, Day -1, Days 2-4, Days 6-14,Days 16-18, Days 20-21 and Day 24 (End of Study Visit/Early Termination Visit)
Query!
Secondary outcome [12]
0
0
To assess the safety of oral dosing of radiprodil co-administered with digoxin
Query!
Assessment method [12]
0
0
Change from baseline in clinical laboratory parameters(hematology, coagulation, clinical chemistry, and urinalysis). Clinical laboratory results assessed using blood and urine samples and will be classified as normal, abnormal not clinically significant (NCS), or abnormal CS.
Query!
Timepoint [12]
0
0
Clinical lab parameters- Screening, Day -1, Days 2-4, Days 6-14,Days 16-18, Days 20-21 and Day 24 (End of Study Visit/Early Termination Visit)
Query!
Secondary outcome [13]
0
0
To assess the safety of oral dosing of radiprodil co-administered with rosuvastatin
Query!
Assessment method [13]
0
0
Change from baseline in clinical laboratory parameters(hematology, coagulation, clinical chemistry, and urinalysis). Clinical laboratory results assessed using blood and urine samples and will be classified as normal, abnormal not clinically significant (NCS), or abnormal CS.
Query!
Timepoint [13]
0
0
Clinical lab parameters- Screening, Day -1, Days 2-4, Days 6-14,Days 16-18, Days 20-21 and Day 24 (End of Study Visit/Early Termination Visit)
Query!
Secondary outcome [14]
0
0
To assess the safety of oral dosing of radiprodil co-administered with omeprazole
Query!
Assessment method [14]
0
0
Clinical laboratory results assessed using blood and urine samples and will be classified as normal, abnormal not clinically significant (NCS), or abnormal CS.
Query!
Timepoint [14]
0
0
Clinical lab parameters- Screening, Day -1, Days 2-4, Days 6-14,Days 16-18, Days 20-21 and Day 24 (End of Study Visit/EarlyTermination Visit)
Query!
Secondary outcome [15]
0
0
To assess the safety of oral dosing of radiprodil co-administered with oral warfarin.
Query!
Assessment method [15]
0
0
C-SSRS scores are assessed using the 'baseline-screening' version and the 'since last visit' version at each scheduled time point.
Query!
Timepoint [15]
0
0
Day -1,Day 15, Day 24 (End of Study Visit/Early Termination Visit)
Query!
Secondary outcome [16]
0
0
To assess the safety of oral dosing of radiprodil co-administered with midazolam
Query!
Assessment method [16]
0
0
C-SSRS scores are assessed using the 'baseline-screening' version and the 'since last visit' version at each scheduled time point.
Query!
Timepoint [16]
0
0
Day -1,Day 15, Day 24 (End of Study Visit/Early Termination Visit)
Query!
Secondary outcome [17]
0
0
To assess the safety of oral dosing of radiprodil co-administered with digoxin.
Query!
Assessment method [17]
0
0
C-SSRS scores are assessed using the 'baseline-screening' version and the 'since last visit' version at each scheduled time point.
Query!
Timepoint [17]
0
0
Day -1,Day 15, Day 24 (End of Study Visit/Early Termination Visit)
Query!
Secondary outcome [18]
0
0
To assess the safety of oral dosing of radiprodil co-administered with rosuvastatin
Query!
Assessment method [18]
0
0
C-SSRS scores are assessed using the 'baseline-screening' version and the 'since last visit' version at each scheduled time point.
Query!
Timepoint [18]
0
0
Day -1,Day 15, Day 24 (End of Study Visit/Early Termination Visit)
Query!
Secondary outcome [19]
0
0
To assess the safety of oral dosing of radiprodil co-administered with omeprazole
Query!
Assessment method [19]
0
0
C-SSRS scores are assessed using the 'baseline-screening' version and the 'since last visit' version at each scheduled time point.
Query!
Timepoint [19]
0
0
Day -1,Day 15, Day 24 (End of Study Visit/Early Termination Visit)
Query!
Eligibility
Key inclusion criteria
- Healthy male and female adults between 18 and 55 years of age, inclusive, at Screening.
* Body mass index (BMI) between 18 and 32 kg/m2 (inclusive) and weighs at least 50 kg at Screening.
* Female participants must be non-lactating and of non-child-bearing potential.
* Male participants if engaging in sexual intercourse with a female partner who could become pregnant must agree to use adequate contraception.
* Participant is of Caucasian origin (note: people of Filipino, Chinese, Japanese, Korean, Vietnamese or Asian-Indian origin are excluded due to higher exposure following rosuvastatin administration).
* Ability to provide signed informed consent and to understand and comply with the requirements of the study including dietary requirements and requirement to stay confined on site for the duration of the study
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
55
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
* History of contraindications or hypersensitivity to radiprodil or any components of the formulations or history of hypersensitivity to warfarin, midazolam, digoxin, rosuvastatin, omeprazole, or vitamin K.
* Female participants who are pregnant, breastfeeding, or have a positive pregnancy test at Screening.
* History or presence of significant (in the opinion of the PI) cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, urologic, neurological, malignancy, psychiatric disease, or brain surgery or injury.
* Any surgical or medical condition that, in the opinion of the PI, could interfere with the absorption, distribution, metabolism, or excretion of the drug.
* History of any CS allergic conditions (including drug allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated, asymptomatic seasonal allergies at time of dosing on Day 1).
* History of illicit drug abuse or alcohol abuse use within 2 years of Screening.
* History of suicide attempts or deliberate self-harm, or a score of 4 or 5 on ideation or any suicidal behavior on the C-SSRS.
* Routine consumption of more than 2 units of alcoholic beverages per day or more than 14 units per week (a unit of alcohol is equivalent to 1 can of beer, 1 glass of wine, or the equivalent of 1 alcoholic drink).
* Routine consumption of an average of more than five (5) 240 mL servings of coffee or other caffeinated beverages per day.
* A positive test result for amphetamines, barbiturates, benzodiazepines, cocaine, methadone, methamphetamines, opiates, methylenedioxymethamphetamine, phencyclidine, tetrahydrocannabinol, cotinine, or alcohol at Screening or Day -1.
* Use of marijuana (including prescribed marijuana) within 30 days of Day -1.
* Use of tobacco-containing products and nicotine or nicotine containing products in the 2 months prior to Day 1.
* Use of any IP and prescription drug within 30 days of Day -1 or within 5 half-lives whichever is longer.
* Use of any over-the-counter (OTC) medication, including herbal products within the 14 days or 5 half-lives prior to dosing, whichever is longer.
* Any vaccine within 7 days of Day -1.
* Acute illness within 14 days of study Day 1.
* Surgery within the past 90 days prior to Day 1.
* Any CS ECG abnormality at Screening.
* Received an IP in any clinical trial within 30 days of Day -1.
* Women of childbearing potential using oral, injected or implanted hormonal contraception.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Not applicable
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
20/05/2025
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/08/2025
Query!
Actual
Query!
Sample size
Target
18
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Nucleus Network Melbourne - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3004 - Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
GRIN Therapeutics, Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Avance Clinical Pty Ltd.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a Phase 1, open-label, 3-period study to determine radiprodil's potential to act as a perpetrator of cytochrome P-450 (CYP) metabolic pathways and transporter pathways. The study will evaluate the pharmacokinetics (PK) and safety effects of co-administration of radiprodil with oral midazolam, rosuvastatin, warfarin, digoxin, and omeprazole in healthy adult subjects. The study will be conducted in 1 cohort of healthy adult participants only.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06975605
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Ofer Gonen, Doctor
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+61 1800243733
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06975605
Download to PDF